Latest Articles

  • Cardiac mass: Tumor or thrombus? (July 2017)
    Mahmoud Abdelghany, MD, Moustafa Elsheshtawy, MD and Hani Kozman, MD
    Cleveland Clinic Journal of Medicine September 2017, 84 (9) 659; DOI: https://doi.org/10.3949/ccjm.84c.09003

    Readers comment on cardiac masses (July 2017).

  • Channeling the flow of medical information
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine March 2017, 84 (3) 178-179; DOI: https://doi.org/10.3949/ccjm.84b.03017

    Accesssing information today is like drinking from a firehose. We need some kind of valve to adjust the flow.

  • Hypertrophic osteoarthropathy: Uncommon presentation of lung cancer
    M. Amrutha, MBBS and T. P. Rajagopal, MD
    Cleveland Clinic Journal of Medicine April 2017, 84 (4) 270-272; DOI: https://doi.org/10.3949/ccjm.84a.15167

    The patient presented with bilateral ankle joint pain, swelling of the ankles and wrists, and digital clubbing.

  • Radiation-induced heart disease: A practical guide to diagnosis and management
    Eoin Donnellan, MD, Dermot Phelan, MD, PhD, Cian P. McCarthy, MD, Patrick Collier, MD, PhD, Milind Desai, MD and Brian Griffin, MD
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 914-922; DOI: https://doi.org/10.3949/ccjm.83a.15104

    Unfortunately, radiotherapy for breast cancer or lymphoma can damage the heart.

  • Thrombolysis in submassive pulmonary embolism: Finding the balance
    Carlos L. Alviar, MD and Gustavo A. Heresi, MD
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 933-936; DOI: https://doi.org/10.3949/ccjm.83a.16099

    In massive pulmonary embolism, thrombolytic therapy is usually indicated; in submassive cases the decision is not so clear.

  • Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
    Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
    Ali Ataya, MD, Jessica Cope, PharmD, Abbas Shahmohammadi, MD and Hassan Alnuaimat, MD
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 923-932; DOI: https://doi.org/10.3949/ccjm.83a.15116

    The risk of hemorrhage is signifi cant, and the benefi t is unclear. A one-treatment-for-all approach cannot be applied.

  • Women’s health 2016: An update for internists
    Pelin Batur, MD, NCMP, CCD, Eleanor Bimla Schwarz, MD, MS, Judith M. E. Walsh, MD, MPH and Kay M. Johnson, MD, MPH
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 905-913; DOI: https://doi.org/10.3949/ccjm.83a.16098

    Important studies of urinary tract infections, bisphosphonates, ovarian cancer screening, and contraception.

  • When should an indwelling pleural catheter be considered for malignant pleural effusion?
    Abdul Hamid Alraiyes, MD, FCCP, Kassem Harris, MD, FCCP and Thomas R. Gildea, MD, MS, FCCP
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 891-894; DOI: https://doi.org/10.3949/ccjm.83a.15075

    Consider catheter placement if symptoms and effusions recur or if pleurodesis fails.

  • Abdominal pain under immunosuppressive conditions
    Takayo Ota, MD, PhD, Masanobu Nakano, MSc, Noriko Tanaka, MD, Tomohiro Suzumura, MD, PhD, Nozomi Miyatake, BPharm, Yoshikazu Hasegawa, MD, PhD, Tomohiro Ozaki, MD, Hiroshi Tsukuda, MD and Masahiro Fukuoka, MD, PhD
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 874-875; DOI: https://doi.org/10.3949/ccjm.83a.15143

    A cancer patient receiving corticosteroids for a brain metastasis developed emphysematous cystitis and psoas muscle abscess.

  • Taurine, energy drinks, and neuroendocrine effects
    Jonathan J. Caine, MD and Thomas D. Geracioti, MD
    Cleveland Clinic Journal of Medicine December 2016, 83 (12) 895-904; DOI: https://doi.org/10.3949/ccjm.83a.15050

    Taurine is a major ingredient in popular energy drinks, but little is known about its neuroendocrine effects.

Pages